INS and Hypoglycemia: Further improvements in reducing the pharmacological variability of rapid- and long-acting insulin would be expected to lower the risk of hypoglycaemia and hyperglycaemia, as well as simplify and perhaps also encourage, optimal insulin titration in real-life clinical practice.